Back to today’s briefing

Story perspectives

Obesity Breakthroughs: Amgen and Novo Nordisk's Weight Loss Wins

6/24/2025

50 6

Summary

Amgen Innovates Obesity Treatment

Amgen's MariTide is making waves in the fight against obesity, with phase 2 trial participants shedding up to 20% of their body weight in just a year. Not to be outdone, Novo Nordisk's CagriSema has shown even greater promise, helping users lose around 23%. These breakthroughs could revolutionize obesity treatment.

Summary

Novo Nordisk Terminates Partnership

Novo Nordisk has severed ties with Hims & Hers Health, citing worries over counterfeit sales of its weight-loss drug, Wegovy. This move comes in light of FDA regulations on compounded drugs. In the wake of the announcement, Hims & Hers' stock plummeted 31%, as the company stood firm on its commitment to patient choice despite rising safety concerns.

1 of 2

Amgen Innovates Obesity Treatment

Amgen's MariTide is making waves in the fight against obesity, with phase 2 trial participants shedding up to 20% of their body weight in just a year. Not to be outdone, Novo Nordisk's CagriSema has shown even greater promise, helping users lose around 23%. These breakthroughs could revolutionize obesity treatment.

1 / 2